CytoDyn Inc. (CYDY)
OTCMKTS
· Delayed Price · Currency is USD
0.3389
-0.0091 (-2.63%)
May 30, 2025, 3:58 PM EDT
CytoDyn Revenue
Revenue
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
9
Market Cap
427.05M
Revenue Chart
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Endo Inc. | 1.73B |
Veradigm | 588.02M |
Tian'an Technology Group | 1.78M |
Elite Pharmaceuticals | 70.00M |
Glass House Brands | 215.62M |
Northwest Biotherapeutics | 1.47M |
Silence Therapeutics | 27.70M |
American Oncology Network | 1.76B |
CytoDyn News
- 4 days ago - A Penny Stock To Watch In Challenging Cancer Space - Benzinga
- 17 days ago - CytoDyn Releases ESMO Breast Cancer Meeting Poster - GlobeNewsWire
- 18 days ago - CytoDyn highlights potential of lead drug against solid tumors with new data - Seeking Alpha
- 19 days ago - CytoDyn Announces Data Suggesting Novel Mechanism of Action of Leronlimab for the Treatment of Solid Tumors - GlobeNewsWire
- 26 days ago - CytoDyn appoints Robert Hoffman as CFO - Seeking Alpha
- 26 days ago - CytoDyn Appoints Biotech Veteran Robert E. Hoffman as Chief Financial Officer - Benzinga
- 26 days ago - CytoDyn Appoints Biotech Veteran Robert E. Hoffman as Chief Financial Officer - GlobeNewsWire
- 4 weeks ago - CytoDyn Leadership Team To Attend ESMO Breast Cancer Meeting in Munich, Germany - GlobeNewsWire